
Medifast (MED) Stock Forecast & Price Target
Medifast (MED) Analyst Ratings
Bulls say
Medifast Inc. has reported an encouraging increase in engagement metrics on its newly enhanced website, specifically highlighting a double-digit rise in average session time, which suggests growing interest in its products. The company is optimistic about potential improvement in sales per Coach in 4Q25 and anticipates a resumption of year-over-year growth in Coach numbers in the first half of 2026, fueled by signs of recovery in key underlying metrics. Additionally, Medifast has achieved significant cost savings and is poised for a projected sales growth of 6% year-over-year in 2026, reinforcing its commitment to delivering value to its stakeholders.
Bears say
Medifast Inc.'s financial outlook remains negative due to declining sales estimates, with a reduction in full-year sales projections to -21% year-over-year and a forecast of flat sales for the fourth quarter of 2025. The company's operating margin has significantly decreased to 0.6%, demonstrating a challenging cost structure amidst lower-than-expected return on investment and reduced advertising expenditures. Additionally, free cash flow has sharply decreased, projected at less than $30 million for 2024 compared to $138 million in 2023, raising concerns about financial sustainability without substantial cost-cutting measures implemented.
This aggregate rating is based on analysts' research of Medifast and is not a guaranteed prediction by Public.com or investment advice.
Medifast (MED) Analyst Forecast & Price Prediction
Start investing in Medifast (MED)
Order type
Buy in
Order amount
Est. shares
0 shares